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Background: Patients unable to receive surgery for stage I non-small 
cell lung cancer (NSCLC) can undergo conventional radiotherapy 
(ConvRT), stereotactic body radiotherapy (SBRT), or no treatment 
(NoTx). This study assessed patterns of care and disparities in the 
receipt of each of these treatments.
Methods: The study included patients in the National Cancer 
Database from 2003 to 2011 with T1-T2N0M0 inoperable lung can-
cer (n = 39,822). Logistic regressions were performed to determine 
predictors of receiving any radiation versus NoTx and for receiving 
SBRT versus ConvRT.
Results: Treatment with radiation was significantly less likely in 
blacks (odds ratio, OR 0.65) and Hispanics (OR 0.42) compared with 
whites. Treatment with SBRT versus ConvRT was more likely in an 
academic research program (OR 2.62) and a high-volume facility 
(OR 7.00) compared with community cancer programs or low-vol-
ume facilities. In 2011, use of SBRT, ConvRT, and NoTx was 25%, 
28%, and 46% for patients in a community cancer center versus 68%, 
11%, and 21%, respectively, in an academic center (p < 0.0001).
Conclusion: There were marked institutional and socioeconomic 
variations in the treatment of inoperable stage I NSCLC. These 
results suggest that removal of barriers to receive radiation therapy 
and particularly improved access to SBRT may meaningfully improve 
survival in this disease.
Key Words: Stereotactic body radiotherapy, Lung cancer, Stage I, 
Radiation.
(J Thorac Oncol. 2015;10: 264–271)
Although surgical resection has been the traditional stan-dard-of-care for curative therapy of stage I non-small cell 
lung cancer (NSCLC), a significant percentage of patients are 
inoperable due to comorbid conditions.1 This population was 
historically treated with conventionally fractionated radio-
therapy (conventional radiotherapy, ConvRT), which necessi-
tated daily treatment more than 6 to 8 weeks, and the survival 
outcomes were disappointing.2–5 In fact, the survival after 
nonsurgical treatment was perceived to be so poor that some 
patients were observed without local therapy (no treatment, 
NoTx) under the assumption that any small survival benefit 
from treatment would be largely mitigated by the patients’ 
competing risks of mortality.6, 7
Although inoperable stage I lung cancer is not an uncom-
mon entity, there is relatively little information on patterns-of-
care in its management. Smith et al. analyzed the treatment of 
inoperable stage I–II lung cancer in British Columbia, finding 
that only one-third of the patients were treated with curative 
radiotherapy.8 Similar data are relatively lacking in the United 
States, which is important not only to appreciate the drivers of 
an observation approach but also to understand the diffusion 
and use of novel and improved treatment techniques.
Indeed, stereotactic body radiotherapy (SBRT) is a rela-
tively new treatment modality that delivers precise, high-dose 
radiotherapy more than one to five fractions.9 Both retrospec-
tive and prospective studies have shown high local control 
rates with this technique, results that compare favorably with 
the surgical literature. For example, RTOG 0236 was a pro-
spective stage II study of SBRT for inoperable stage I lung 
cancer, and its publication in 2008 revealed a local control 
probability of 97.6% at 3 years. Previous work has also shown 
a survival advantage associated with the use of SBRT.10
In this study, we have used the National Cancer Database 
(NCDB) to characterize the treatment approaches in patients 
with inoperable stage I NSCLC diagnosed between 2003 and 
2011. Our focus included analyzing the predictors of observa-
tion versus active treatment and SBRT versus ConvRT, paying 
particular notice to treatment trends over time, socioeconomic 
disparities, and institutional characteristics.
METHODS
Database
This study examined the NCDB, which is a hospital-
based cancer registry that collects data from the American 
College of Surgeons–Commission on Cancer accredited facil-
ities.11 The database is sponsored by the American College 
of Surgeons and the American Cancer Society and includes 
approximately 70% of all malignant cancers diagnosed in the 
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United States. The database contains information on patient 
demographics, primary tumor site, histology, site at diagnosis, 
insurance status, first course of treatment, and overall survival. 
The NCDB has established specific criteria to ensure that the 
data submitted meets certain quality benchmarks.
Data and Study Population
Eligible patients had histologically confirmed first pri-
mary NSCLC and received all or part of their first course of 
treatment at Commission on Cancer–accredited facilities (if 
treated at all). In the database, there were 50,603 patients 
with stage I NSCLC treated from 2003 to 2011 who did not 
undergo surgery. Patients were stratified into three cohorts: 
SBRT, ConvRT to a minimum dose of 60 Gy, and no radia-
tion therapy, the latter of whom did not receive any radiation 
therapy and survived a minimum of 4 months. The 4-month 
survival criteria was implemented to exclude patients with 
such short survival that they would presumably been ineli-
gible for any therapy.12 Patients not meeting the criteria for 
one of these three cohorts were excluded from the analy-
sis, including patients with no information on radiation 
technique. A total of 39,822 patients met these eligibility 
criteria.
Statistical Analysis
Candidate variables were grouped into four catego-
ries: clinical (e.g., histology, T stage, age, Charlson–Deyo 
index), time, socioeconomic (e.g., race, insurance status), 
and institutional (treatment volume, facility type). Facility 
types were designated by the Commission on Cancer crite-
ria and include: (1) community cancer programs, (2) com-
prehensive community cancer programs, and (3) academic 
research programs. Community cancer programs treat 
between 100 and 500 cancer patients a year and have a full 
range of services for cancer. Comprehensive community 
cancer programs treat at least 500 cancer patients a year and 
offer the same range of services. Academic research pro-
grams are affiliated with medical schools, have residency 
programs, and conduct ongoing cancer research. The treat-
ment volume category was calculated by examining the 
overall total number of patients treated by each facility and 
dividing it into equal sized tertiles.13 Low, medium, and 
high volume facilities treated a total of 1 to 12, 13 to 35, 
and 36 to 279 patients, respectively. The follow-up time was 
defined as the time from diagnosis to date of death from any 
cause or from diagnosis to date of last contact for those who 
were alive at last contact.
Differences in treatment (NoTx vs. ConvRT vs. SBRT) 
by clinical, socioeconomic, and institutional characteristics 
were estimated using the chi-squared test. We also deter-
mined predictors of treatment with SBRT versus ConvRT 
among patients who received some modality of radiotherapy. 
Multivariable stepwise logistic regressions were performed to 
determine independent predictors of any treatment (ConvRT 
or SBRT) versus no treatment and independent predictors 
of SBRT among patients treated with radiotherapy. Data 
were analyzed using SAS version 9.3, JMP version 10 (SAS 
Institute, Cary, NC) and SPSS v21 (IBM, Armonk, NY).
RESULTS
Patient Characteristics
A total of 39,822 patients were diagnosed with clini-
cal stage I NSCLC from 2003 to 2011 and met the eligibil-
ity criteria for this study. Of this group, 27% (n = 10,687) 
of the patients underwent SBRT, 30% (n = 12,163) received 
daily fractionated ConvRT, and 43% (n = 16,972) underwent 
no radiation therapy. Patient characteristics are shown in 
Table 1. Of note, 8.1% of the 18 to 59 years of age cohort 
were not insured compared with 0.7% of the rest of the 
cohort (p < 0.001). Also, throughout the time period there 
were differences in where patients received treatment with 
13.1%, 64.7%, and 22.2% being treated at community can-
cer programs, comprehensive community cancer programs, 
and academic research programs, respectively, in 2003. This 
changed to 8.7%, 58.4%, and 32.9% being treated at com-
munity cancer programs, comprehensive community cancer 
programs, and academic research programs, respectively, in 
2011 (p < 0.0001).
Among the cohort, 3% received SBRT from 2003 to 
2005 and 44% received SBRT from 2009 to 2011. The per-
centage of patients who did not receive radiation therapy 
treated from 2003 to 2005 versus 2009 to 2011 dropped from 
55% to 35%, and a similar decrease was seen in the percent-
age of patients treated with ConvRT, which went from 42% to 
21% over that period (Fig. 1).
Predictors of Receiving Any Radiation Therapy
The likelihood of undergoing radiation therapy (either 
SBRT or ConvRT) versus no radiation therapy is shown in 
Table 2. Older patients and individuals with T1 stage were 
more likely to undergo treatment. There was a significant 
increase in active treatment over the time period of the study. 
Indicators of less privileged socioeconomic status were 
strongly related to the probability of receiving treatment: it 
was less likely in blacks (odds ratio, OR, 0.64) and Hispanics 
(OR 0.42), and uninsured patients were markedly less likely 
to undergo treatment. Institutional characteristics also influ-
enced treatment choice, as patients treated at academic and 
high-volume institutions were significantly more likely to 
receive treatment. Figure 2 shows the proportion of patients 
treated with SBRT, ConvRT, and NoTx by institution type 
and year. In 2011, use of SBRT, ConvRT, and NoTx was 25%, 
28%, and 46% for patients in a community cancer center ver-
sus 68%, 11%, and 21%, respectively, in an academic center 
(p < 0.0001).
Radiotherapy Technique
Predictors of treatment with SBRT versus conventional 
radiation therapy among patients who received treatment are 
shown in Table 3. The multivariable analysis echoes the prior 
model analyzing predictors of any treatment. In particular, 
black race was significantly associated with a lower prob-
ability of receiving SBRT (OR 0.7). Treatment at academic 
research programs and high treatment volume facilities were 
associated with a higher likelihood of receiving SBRT (OR 
2.67 and 6.6, respectively).
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TABLE 1.  Patient Characteristics Among Clinical Stage I Inoperable NSCLC Patients, National Cancer Database 2003 to 2011
Categories
All Patients  
(n = 39,822)
No Radiation Therapy  
(n = 16,972)
Radiation Therapya  
(n = 22,850) p Value
Conventional 
Radiation Therapy  
(n = 12,163)
Stereotactic Body 
Radiation Therapy  
(n = 10,687) p Value
Clinical factors
  Gender 0.895 <0.0001
   Male 49.0% 42.6% 57.4% 55.8% 44.2%
   Female 51.0% 42.7% 57.3% 50.8% 49.2%
  Comorbidity index 0.025 <0.0001
   0 59.7% 43.2% 56.8% 52.0% 48.0%
   1 26.2% 41.8% 58.2% 54.9% 45.1%
   2+ 14.1% 41.9% 58.1% 55.2% 44.8%
  T stage <0.0001 <0.0001
   T1 61.4% 39.7% 60.3% 45.3% 54.7%
   T2 38.6% 47.3% 52.7% 67.8% 32.2%
  Age at diagnosis <0.0001 <0.0001
   18–59 8.1% 55.5% 44.5% 57.4% 42.6%
   60–69 22.4% 42.7% 57.3% 54.6% 45.4%
   70–79 39.1% 40.2% 59.8% 53.8% 46.2%
   80+ 30.4% 42.2% 57.8% 50.7% 49.3%
  Histology <0.0001 <0.0001
   Adenocarcinoma 42.1% 46.2% 53.8% 46.3% 53.7%
   NSCLC (not 
otherwise specified)
22.2% 41.7% 58.3% 58.5% 41.5%
   Squamous 33.4% 38.3% 61.7% 56.8% 43.2%
   Large cell 2.4% 49.0% 51.0% 66.3% 33.8%
Socioeconomic factors
  Race/ethnicity <0.0001 <0.0001
   White 85.8% 40.9% 59.1% 52.7% 47.3%
   Black 9.7% 51.9% 48.1% 59.4% 40.6%
   Others 2.5% 51.4% 48.6% 51.7% 48.3%
  Hispanic 2.0% 62.8% 37.2% 54.2% 45.8%
  Insurance status <0.0001 <0.0001
   Not insured 1.3% 64.8% 35.2% 69.4% 30.6%
   Private insurance/ 
managed care
15.7% 48.7% 51.3% 54.1% 45.9%
   Medicaid 3.6% 52.0% 48.0% 59.2% 40.8%
   Medicare 77.6% 41.0% 59.0% 52.7% 47.3%
   Other government 1.8% 22.0% 78.0% 52.1% 47.9%
Institutional factors
  Facility type <0.0001 <0.0001
   Community cancer 
program
11.4% 56.9% 43.1% 84.0% 16.0%
   Comprehensive 
community cancer 
program
60.4% 43.8% 56.2% 55.9% 44.1%
   Academic research 
program
28.1% 34.3% 65.7% 40.2% 59.8%
  Facility volume <0.0001 <0.0001
   Low 33.5% 55.3% 44.7% 77.5% 22.5%
   Medium 33.2% 43.2% 56.8% 59.7% 40.3%
   High 33.3% 29.3% 70.7% 32.6% 67.4%
  Year of diagnosis <0.0001 <0.0001
   2003–2005 23.9% 54.6% 45.4% 92.5% 7.5%
   2006–2008 32.6% 44.2% 55.8% 61.8% 38.2%
   2009–2011 43.5% 34.9% 65.1% 32.7% 67.3%
aRadiation treatment cohort includes any patients who received conventional or stereotactic body radiotherapy.
NSCLC, non-small cell lung cancer.
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DISCUSSION
This study has revealed a substantial shift in the pat-
terns of treatment for inoperable stage I NSCLC. There has 
been a dramatic reduction in the number of patients who were 
observed without active treatment, and a parallel marked 
increase in the use of SBRT.
Historically, patients who were ineligible to undergo 
surgical resection would be required to visit a radiation ther-
apy clinic daily for several weeks to receive conventional radi-
ation therapy. Thus one explanation for our results is that the 
time and effort associated with conventional radiation therapy 
may have been a significant barrier to receiving treatment, as 
the falling rates of observation were countered by the rising 
prevalence of SBRT. A complementary explanation is that the 
presumptive higher success of SBRT supported the decision 
for compromised individuals to attempt curative treatment, 
despite some baseline risk of increasing pulmonary morbidity 
from treatment. A recent phase II study randomized patients 
between ConvRT and SBRT. The study found no significant 
difference in overall survival in patients who received SBRT 
versus ConvRT (41.3 months vs. 42.1 months, respectively). 
It concluded that SBRT should be considered as a standard 
treatment for early stage inoperable lung cancer due to less 
toxicity and patient convenience with less treatment visits and 
improved cost-effectiveness compared with ConvRT.14 There 
are cancer programs where due to financial restrictions or lack 
of expertise it may be difficult to implement a stereotactic pro-
gram. In this setting, it may be appropriate to use standard 
3D conformal radiotherapy techniques with a hypofraction-
ated approach which has also been associated with excellent 
outcomes and requires less treatment visits compared with the 
standard conventional approach (30+ treatment visits).15
We found substantial variations in the likelihood of receiv-
ing any curative treatment and the probability of receiving SBRT 
among individuals who were irradiated. As shown, a significantly 
higher proportion of patients were diagnosed and treated at aca-
demic research programs in the later years which may explain 
the higher proportion of patients receiving SBRT in later years, 
as academic centers may have been early adopters of this new 
technology. Also, black patients and uninsured patients were 
dramatically less likely to undergo treatment for their early stage 
inoperable lung cancer. This is consistent with previous research 
which has shown black cancer patients are less likely receive sur-
gery or chemotherapy compared to white cancer patients.16–18 In 
patients who did undergo therapy, black patients and individuals 
with no insurance were also less likely to receive SBRT. Further 
efforts are needed to better understand and decrease these dis-
parities, whose genesis is likely multifactorial.19
FIGURE 1.  Treatment of early stage inoperable lung cancer from 2003 to 2011.
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TABLE 2.  Likelihood of Receiving Radiation Therapya Among Clinical Stage I Inoperable NSCLC Patients, National Cancer 
Database 2003–2011 (n = 39,822)
Categories Odds Ratio 95% (Confidence Limits) p Value
Clinical factors
  Gender
   Male 1.0 (ref) 0.75
   Female 1.00 0.97 - 1.06
  Comorbidity index
   0 1.0 (ref) 0.50
   1 1.03 0.98–1.08
   2+ 1.01 0.95–1.07
  T stage
   T1 1.0 (ref) <0.0001
   T2 0.83 0.79–0.86
  Age at diagnosis <0.0001
   18–59 1.0 (ref)
   60–69 1.41 1.29–1.55
   70–79 1.49 1.36–1.63
   80+ 1.39 1.26–1.51
  Histology
   Adenocarcinoma 1.0 (ref) <0.0001
   NSCLC (not otherwise specified) 1.42 1.35–1.50
   Squamous 1.50 1.43–1.58
   Large cell 1.1 0.96–1.27
Socioeconomic factors
  Race/ethnicity
   White 1.0 (ref) <0.0001
   Black 0.64 0.60–0.69
   Others 0.68 0.59–0.77
   Hispanic 0.42 0.36–0.49
  Insurance status
   Not insured 1.0 (ref) <0.0001
   Private insurance/managed care 1.64 1.34–1.99
   Medicaid 1.69 1.36–2.09
   Medicare 2.02 1.67–2.46
   Other government 4.49 3.44–5.84
Institutional factors
  Facility type
   Community cancer program 1.0 (ref) <0.0001
   Comprehensive community 
cancer program
1.11 1.03–1.19
   Academic research program 1.46 1.35–1.59
  Facility volume
   Low 1.0 (ref)
   Medium 1.48 1.40–1.57 <0.0001
   High 2.55 2.40–2.70
  Year of diagnosis
   2003–2005 1.0 (ref) <0.0001
   2006–2008 1.44 1.37–1.53
   2009–2011 2.10 1.99–2.21
aRadiation treatment cohort includes any patients who received conventional or stereotactic body radiotherapy.
NSCLC, non-small cell lung cancer.
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Patients who were aged 18 to 59 years were less likely 
to receive treatment of SBRT compared with older patients. 
As Medicare provides all Americans above the age 65 years 
with health insurance, the age disparity could partially be 
explained by the higher proportion of uninsured patients seen 
in the younger cohort versus the rest of the cohort (8.5% vs. 
0.7%). Younger age could also be a surrogate for worse access 
to appropriate medical care which would be independent of 
TABLE 3.  Likelihood of Receiving Stereotactic Body Radiotherapy versus Conventional Radiation Therapy among Clinical Stage 
I Inoperable NSCLC Patients, National Cancer Database 2003–2011 (n = 22,850)
Categories Odds Ratio 95% (Confidence Limits) p Value
Clinical factors
  Gender
   Male 1.0 (ref) <0.0001
   Female 1.17 1.09–1.25
  Comorbidity index
   0 1.0 (ref) <0.0001
   1 0.84 0.78–0.91
   2+ 0.86 0.78–0.94
  T stage
   T1 1.0 (ref) <0.0001
   T2 0.46 0.43–0.50
  Age at diagnosis <0.0001
   18–59 1.0 (ref)
   60–69 1.03 0.88–1.20
   70–79 1.10 0.95–1.29
   80+ 1.25 1.07–1.47
  Histology
   Adenocarcinoma 1.0 (ref) <0.0001
   NSCLC (not otherwise specified) 0.93 0.85–1.02
   Squamous 0.76 0.70–0.82
   Large cell 0.74 0.58–0.94
Socioeconomic factors
  Race/ethnicity
   White 1.0 (ref) <0.0001
   Black 0.71 0.63–0.80
   Others 1.07 0.85–1.34
   Hispanic 0.92 0.69–1.22
  Insurance status
   Not insured 1.0 (ref) 0.001
   Private insurance/managed care 1.99 1.34–2.96
   Medicaid 1.65 1.08–2.52
   Medicare 2.07 1.40–3.05
   Other government 1.72 1.12–2.67
Institutional factors
  Facility type
   Community cancer program 1.0 (ref) <0.0001
   Comprehensive community cancer program 1.68 1.45–1.95
   Academic research program 2.67 2.28–3.13
  Facility volume
   Low 1.0 (ref)
   Medium 1.89 1.72–2.07 <0.0001
   High 6.62 6.02–7.28
  Year of diagnosis
   2003–2005 1.0 (ref) <0.0001
   2006–2008 7.76 6.81–8.84
   2009–2011 30.33 26.65–34.51
NSCLC, non-small cell lung cancer.
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insurance status, and this could explain why younger patients 
were less likely to receive any treatment or treatment with 
SBRT. Health policy initiatives such as the Affordable Care 
Act in the United States which aims to decrease the number 
of nonelderly uninsured patients may help alleviate this issue, 
and their impact on reducing cancer disparities should be the 
subject of future studies.
We also saw significant differences in treatment approach 
among institutions, as academic centers and high-volume hos-
pitals were significantly more likely to deliver both any treat-
ment and SBRT over conventional radiotherapy. Institutional 
characteristics have previously been shown to influence treat-
ment paradigm for stage IIIA NSCLC, and the present findings 
confirm the importance of institutional characteristics in treat-
ment recommendations.20, 21 These findings may be attributable 
to these centers having a higher proportion of multi-disciplin-
ary clinics, tumor boards, and navigation programs which all 
facilitate improved access to care.22 It is critical to understand 
the explanation for these differences and determine whether 
these differences reflect underlying (and uncontrolled within 
this analysis) differences in patient demographics, treatment 
recommendation biases, and/or technology gaps.
This study does have limitations implicit in large retro-
spective database analyses including institution reporting bias. 
Also, the NCDB does not record several important variables, 
such as Karnofsky performance status, weight loss, or tumor 
location (central vs. peripheral) which may have affected the 
treatment received. Another limitation of the study is that sur-
vival information was unavailable for the entire time period 
in this study, and therefore these results cannot be linked to 
survival outcomes.
In conclusion, we have shown variable diffusion of a 
new treatment technique (SBRT) among the general popula-
tion, and we should consider mechanisms to improve access to 
SBRT.23 For example, all patients with early-stage lung cancer 
who are ineligible to undergo surgery should be evaluated by 
a radiation oncologist before excluding curative radiotherapy. 
Similarly, there should be a focus on education and training 
of radiation oncologists in stereotactic techniques, improving 
access to facilities that offer SBRT, and cancer accreditation 
bodies requiring facilities to offer SBRT as a treatment modal-
ity. Based on our data, such relatively straightforward efforts 
may lead to meaningful improvements in survival in this chal-
lenging patient demographic.
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